%0 Journal Article
%T Validation of the FIGO2023 staging system for early-stage endometrial cancer.
%A Wei L
%A Li M
%A Xi M
%J Eur J Surg Oncol
%V 50
%N 9
%D 2024 Jun 21
%M 38941954
%F 4.037
%R 10.1016/j.ejso.2024.108480
%X <B>BACKGROUND: </B>In 2023, the International Federation of Gynecology and Obstetrics (FIGO) updated the endometrial cancer staging system (FIGO2023). Our study aimed to validate the prognostic value of FIGO2023 in patients with early-stage EC (Stage I and Stage II).<BR><B>METHODS: </B>After screening eligible EC patients from the Surveillance, Epidemiology and End Results (SEER) database, Kaplan-Meier cancer-specific survival (CSS) curves were used to evaluate the prognosis of patients with different stages. In addition, AUC, C-index, Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), and Decision curve analysis (DCA) were used to comprehensively compare the efficacy of the new and the old staging system in predicting prognosis.<BR><B>RESULTS: </B>A total of 33,156 patients were enrolled. The introduction of FIGO2023 significantly increased the proportion of stage II patients from 5.53 % to 24.76 %. The FIGO2023 defines different substages for patients, which show significant differences in CSS. Compared with FIGO2009, FIGO2023 performed better in discrimination, goodness of fit and clinical decision making.<BR><B>CONCLUSIONS: </B>Compared with FIGO2009, FIGO2023 had a higher accuracy in predicting CSS in patients with early-stage EC in the SEER database.